A Powerful Approach

Threshold is a biotechnology company focused on the discovery and development of therapeutics based on Tumor Hypoxia, a powerful scientific platform that offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional drugs.

Product Pipeline

TH-302 is a hypoxia-activated prodrug (HAP) for the potential treatment of solid tumors. TH-302, which was discovered at Threshold, is a novel drug candidate that is activated under the metabolic conditions typical of cancer cells. We filed an IND (Investigational New Drug) with the FDA in April 2007 and started a Phase 1 clinical trial in July 2007. We initiated a second clinical trial of TH-302 in August 2008. This Phase 1/2 clinical trial is also focused on treating solid tumors.

Glufosfamide has been investigated for the potential treatment of pancreatic cancer, small cell lung cancer, platinum-resistant ovarian cancer and advanced soft tissue sarcoma. The soft tissue sarcoma trial provided evidence of clinical activity. Additionally, in a phase 2 clinical trial of glufosfamide in combination with gemcitabine for the treatment of advanced pancreatic cancer, the data indicated that glufosfamide plus gemcitabine may benefit patients with chemotherapy naive pancreatic cancer. The Company will be seeking a partner to continue development of glufosfamide in cancer.

2-Deoxyglucose, or 2DG, for the treatment of solid tumors, has been evaluated in a Phase 1 clinical trial alone and in combination with Taxotere.

Experienced Team

The Threshold team is made up of experienced research scientists, and business professionals with successful track records in the biotech industry. Senior management and advisors are authorities in the field of oncology drug discovery and development and have been instrumental in building numerous industry leading companies including Amgen, Genentech, Affymax, Camitro, Coulter Pharmaceuticals, Gilead, Maxygen, Protein Design Labs and Scripps.

A Significant Unmet Need

Our product candidates are focused on treating patients with significant unmet medical needs. Cancer is the second leading cause of death in the United States after cardiovascular disease. The American Cancer Society estimates that 559,650 people died from cancer in the United States in 2007. Many cancers, such as pancreatic, lung and liver cancer, have few effective treatments and very low survival rates.